Improved Epilepsy and Speech Outcomes with Human Embryonic Stem Cell Therapy in Children with Cerebral Palsy

Geeta Shroff¹.

¹ Director, Nutech Mediworld, New Delhi, India.

Contact information:
Geeta Shroff.
Address: Nutech Mediworld, H-8, Green Park Extension, New Delhi-110016.
Tel: +91 11 26180039
Fax: +91 11 26560089
geetashroff@hotmail.com

Keywords
Cerebral Palsy (CP); Gross Motor Function Classification System (GMFCS); Stem Cells; Human Embryonic Stem Cell (Hesc) Therapy; Epilepsy; Speech

Abstract

Introduction: Cerebral Palsy (CP) is a group of permanent neurological disorders which is prevalent in children of neonatal age and is often associated with epilepsy and speech disorders. The various conventional treatments and therapies available so far are unable to treat these comorbidities. In this study, we aimed to evaluate 101 patients with CP having speech disorders and epilepsy. The patients were treated using human embryonic stem cells (hESC) therapy and assessed by Gross Motor Function Classification System-Expanded and Revised (GMFCS-E & R) score.

Materials and Methods: Patients were given hESCs via different routes of administration for duration of 8 weeks and evaluated before and after the treatment on the basis of their levels of gross and motor function of improvement, i.e., frequency of the epileptic attacks and ability to speak. Single photon emission computed tomography (SPECT) scan investigations were also performed to support the studies.

Results: There was an improvement in 96.61% of the epileptic patients and 91.39% of the patients with speech disorder. Of 59 patients affected with epilepsy, 18 patients had shown complete disappearance of epileptic episodes; and of 93 patients affected with speech, 27 patients became completely verbal.

Conclusion: Hence, hESC therapy might be beneficial in patients with CP having epilepsy and speech disorders.
Introduction
Cerebral Palsy (CP) is one of the most common lifelong disorders that appear in infancy or early childhood. The prevalence estimates for worldwide population-based studies for CP ranges from 1.5 to 4 per 1,000 live births or children of a defined age range. Latest survey conducted by CDC’s Autism and Developmental Disabilities Monitoring (ADDM) Network reports that about 1 in 323 children is identified with CP [1, 2].

CP can be congenital; caused due to preterm delivery, multiple gestations, and other pregnancy complications, genetic abnormalities, maternal infections/fevers, or fetal injury or it can be acquired, where brain infections such as bacterial meningitis or viral encephalitis, problems with blood flow to the brain, or head injury from a motor vehicle accident, a fall, or child abuse can lead to cause CP [3-5].

It is associated with major disabilities of the body such as disturbances of sensation, perception, cognition, communication, behavior, epilepsy, and secondary musculoskeletal problems [6, 7]. Co-morbidities in CP affect the overall health and quality of life. It is observed that the patients with CP have most common symptoms of speech motor disorder such as dysarthria and neurological disorder such as epilepsy [8-11].

Most of the symptoms of CP do not have specific and curative treatments. Majority of the optimal therapies designed so far do not yield much effective results. The reasons behind the failures are usually variations in quality of treatment required and different symptoms of different age groups [12]. Besides available conventional treatments, various stem cell therapies like umbilical cord blood stem cells (UCBSCs), bone marrow stem cells, induced pluripotent stem cells (iPSCs) have also been studied for CP patients. These cells have high potential of pluripotency and can differentiate into various other tissues and can also restore neuronal damage. Nevertheless, stem cells have been used in various neurological disorders but still future trials are needed to confirm their long-term efficacy [12-15]. Therefore, there is a need to develop clinically significant techniques to treat CP which can target specific problem.

We have previously demonstrated the safety and efficacy of human embryonic stem cell (hESC) therapy in our patients with CP, and there was a remarkable clinical improvement observed in them [16]. The present study is a subgroup analysis of the patients with CP who had epilepsy and speech disorders before initiating hESC therapy.

Materials and Methods
Ethical statement
The study protocol was approved by the Independent Institutional Ethics Committee. The institutional committee for stem cell research and therapy of Nutech Mediworld reported the clinical study to National Apex Body. The study was conducted in accordance to the Declaration of Helsinki.

Study characteristics and design
This study was a retrospective analysis for epilepsy and speech outcomes of a total cohort of 101 CP patients who were treated with hESC therapy. The study was conducted from 01 October 2007 to 31 July 2013 at Nutech Mediworld. The patients were diagnosed with CP elsewhere and referred to us were included in the study. We have previously published the data of these patients with CP assessed using GMFCS scoring [16, 17].

The hESCs were derived from a single, spare, expendable, pre-implantation stage fertilized ovum taken during natural in-vitro fertilization (IVF) process with due consent of the donor. The cells were cultured and maintained as per our in-house patented technology (United States Granted Patent No US 8592, 208, 52) in a good manufacturing practice (GMP), good laboratory practice (GLP) and good
tissue practice (GTP) compliant certified laboratory [18, 19]. The safety and efficacy of the cell line has earlier been established. We have used these cell lines to treat over 1300 patients with diverse ailments [19].

### Study Design
The detailed study design is elaborated elsewhere [16]. The patients with CP were initially tested for hypersensitivity reactions with hESC (0.25 mL hESC injected subcutaneously). Afterwards, they entered the treatment phase which lasted for 8 weeks, where 0.25 mL (≤ 4 million cells) hESCs were administered through intramuscular (IM) route once daily and 1 mL of hESC (≤16 million cells) was administered twice every 7 days through intravenous (IV) route. In addition, each patient had received a dose of hESCs by caudal route which could be repeated every 5-14 days.

The efficacy of hESC therapy was evaluated based on the Gross Motor Function Classification System – Expanded and Revised (GMFCS - E & R) score. Single-photon emission computed tomography (SPECT) scan of the patients was performed before and after the therapy [16, 20].

### Epilepsy and Speech levels of scoring
The epilepsy and speech outcomes were evaluated on Levels 5 (Bad) - 1 (Good). Table 1 shows the different levels of the scale that we used to score epilepsy and speech disorders in these patients.

### Results

#### Patients
Of the 101 patients included in the study, 29 (28.71%) were women and 72 (71.28%) were men. The age of the patients ranged from 30 days to 18 years. Of 101 patients, 59 (58.41%) had epileptic problems and 93 (92.07%) were suffering from speech disorders. The demographic characteristics of all the patients included in this study are summarized in Table 2.

### Table 1. GMFCS - E & R score for Evaluating Epilepsy and Speech Outcomes for CP Patients.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Description</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epilepsy</td>
<td>Less frequent than in 4</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>1-2 times/week or occasionally</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>1-2 times/alternative day</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>1-2 times/day</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Multiple times/day</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Not afflicted in CP</td>
<td>NAA</td>
</tr>
<tr>
<td>Speech</td>
<td>Normal</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Slurred, able to form many words</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Able to form few words</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Able to form single word</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Completely non verbal</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Not afflicted in CP</td>
<td>NAA</td>
</tr>
</tbody>
</table>

NAA: Not afflicted in CP

### Table 2. Demographic Characteristics of 101 Patients with Severe CP who were Treated with hESCs.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>30 days-18 yr</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>Male (n%)</td>
<td>71.28</td>
</tr>
<tr>
<td>Female (n%)</td>
<td>28.71</td>
</tr>
<tr>
<td>Duration of treatment (T1)</td>
<td>56 days (8 weeks)</td>
</tr>
<tr>
<td>Number of epileptic patients (N)</td>
<td>59</td>
</tr>
<tr>
<td>Number of patients with speech disorder (N)</td>
<td>93</td>
</tr>
<tr>
<td>Dose</td>
<td></td>
</tr>
<tr>
<td>hESCs (IM route) once daily</td>
<td>0.23 mL (&lt;4 million cells) hESCs (IM route) once daily and 1 mL of hESC (&lt;16 million cells) every 7 days through IV route.</td>
</tr>
<tr>
<td>1 mL of hESC (&lt;16 million cells) twice every 7 days through IV route.</td>
<td></td>
</tr>
</tbody>
</table>
Efficacy Evaluation

The efficacy studies for epilepsy and speech outcomes were compared at baseline (before treatment) and after treatment using GMFCS-E & R scores.

Changes in Improvement for Epilepsy Patients - Before and after the end of therapy

Figure 1 shows the GMFCS scores for epileptic patients

Overall, of the 59 epileptic patients who received hESC therapy, a considerable improvement was observed in all the patients assessed. At baseline, there were 27 (45.8%) patients at level 5, 13 (22%) patients were at level 4, at level 3 and 2, there were 11(18.6%) and 5(8.5%) patients, respectively. There was a single patient (1.7%) at level 1.

At the end of the therapy, there was a significant improvement among all the patients treated. None of the patients were at level 5 and 4. There were 8 (13.6%) patients at level 3 and 31 (52.5%) patients at level 2. Overall, 18 (30.5%) patients showed complete improvement and reached the stage of normalcy at level 1.

Changes in Improvement for Patients with Speech disorders. Before and after the end of therapy

Figure 2 shows the GMFCS scores for patients with speech disorders

Of 93 patients included for speech disorders, at baseline, 40 (42%) patients were at level 5 who were completely speechless. At level 4, there were 20 (21.5%) patients who could form a single word. There were 15 (16.1%) and 10 (10.8%) patients at level 3 and 2, respectively. After hESC therapy, none of the patient remained non-verbal. There was reported remarkable improvement in 27 (29%) patients, who scored level 1. A total of 48 (51.6%) patients were at level 2, there were 10 (10.8%) patients at level 3 and none of the patients were at level 4 and 5. At the end of study, none of the patients remained babbling and non-verbal.

SPECT scan

At the beginning and at the end of the study, patients underwent SPECT scan. Hypoperfusion was either observed in the left and right part of the brain. The SPECT scan of one of the patient has been illustrated in Figure 3 (a) and (b).
Discussion

Many confounding factors in CP affect the overall quality of life of an individual; of which epilepsy and language/speech disorders are the most frequent [8, 18, 21]. It has been found that 15–60% of children with CP are affected with epilepsy [22]. Such patients suffer frequent attacks of epileptic seizures like generalized tonic clonic, myoclonic/atonic, partial seizures and few of them also are victims of other epileptic associated syndromes viz infantile spasms, west and lennox-gastaut syndrome [23, 24]. Though seizures can be controlled by pharmacotherapy, but epilepsy still remains an area of concern as epilepsy in patients with CP is of severe nature and difficult to control. These attacks sometimes are so scary that the young children get mentally as well as physical harmed [25, 26].

In order to control the seizures and spasms, physicians prescribe various antiepileptic drugs (AEDs) to CP patients, but all these medications either have adverse events such as digestive problems, breathing difficulties, skin conditions, and behavioral or learning issues, so patients don’t benefit much with such treatments [1, 25, 27] or patients have poor response to AEDs. Also, the risk of seizure relapse after AED discontinuation worsens the patient’s condition [3, 28]. Bruck et al showed that most of the CP patients who have epilepsy disorders are often associated with speech disorders too. The severity of speech may have different levels; patients are either completely non verbal or are mono-syllable (not able to form single word); disyllable (not able to form many words) or cannot form sentences. As per the study conducted by Parkes et al and Bax et al (European study); approximately 35% of young people with CP have dysarthria and 60% of children have some kind of communication problems, respectively [6, 29, 30]. There are no such treatments available which can improve speech in CP patients. Though rehabilitation services for speech and language therapy (SLT) are available to improve communication skills, but there are no studies available to support the evidence for the maintenance of these skills in future. SLT also depends on the effectiveness of training provided which may vary with different service providers [30, 31].

Data reported from several retrospective studies and systematic reviews shows that the conventional treatments used to treat CP and its associated symptoms such as botox, baclofen to control muscle spasms and seizures, glycopyrrolate to control drooling and pamidronate to control osteoporosis are...
not the effective treatments to cure it permanently [32-34]. These treatments have limitations to treat CP at GMFCS levels IV and V only [35].

Unlike other cells of the body, the brain cells have a very limited capacity for self-repair as mature and old neurons cannot regenerate. Epilepsy in CP is often caused either due to degeneration of neurons or deficiency and dysfunctioning of neurotransmitters like gamma amino butyric acid (GABA). Thus, it can be controlled by two mechanisms, either by the replacement of damaged or lost neurons or by substitution of physiological mediator [36]. Studies by Naegele et al in animal models have shown that transplanted embryonic stem cells in the developing brain of mouse models of epilepsy can generate dopaminergic, motor, and GABAergic neuron which can control seizures, thus helps in improving the GABAergic function of neurons [37]. hESCs have the capability to restore damaged neurons and replace them with fresh neurons. These cell lines not only raise the seizure threshold but also suppress recurrent spontaneous seizures [38].

In the present study, hESCs after being injected in CP patients, might have migrated to the appropriate sites of injured brain; differentiated into neuronal and glial lineages and integrated and made connections with the host neurons. The transplanted cell lines generated new neurons and received excitatory input from host neurons which in turn generated inhibitory responses like inhibitory neurotransmitter GABA and astrocytes which secretes anticonvulsant factors such as the glial cell-line derived neurotrophic factor (GDNF). It helps to reverse the electrical hyperactivity in the most hyperexcitable parts of brain i.e. hippocampus and substantia nigra that results in seizures [39-42].

Various preclinical and clinical studies are ongoing with different kind of stem cells like mesenchymal stem cells, pluripotent stem cells and bone marrow cells etc to treat CP and its associated comorbidities [27, 43]. Being pluripotent and autologus in nature, stem cells might have a huge potential in treating these disorders. Animal studies have shown promising results; wherein stem cells are able to reduce neuron damage and return motor function, improves cognitive function after any kind of brain injury [44, 45]. Many preclinical studies have demonstrated that stem cell therapy can be effective in treating temporal lobe epilepsy (TLE) [46, 47]. Even FDA has approved a couple of clinical trials based on promising results; two US clinical trials and few other foreign trials using stem cells are ongoing to establish their safety and efficacy for CP [48-50]. Though the ethical concerns and safety issues for using stem cells in humans is still a controversial topic in scientific research; but the scientific community is constantly evolving to tackle this appropriately [45].

hESC therapy developed at our facility is patented, xeno-free and have proven safety and efficacy in various neurological disorders [18]. The safety and effectiveness of hESC treatment for CP patients has also been proven with other radiological investigations such as SPECT in our previous findings [20]. The patients who were admitted at our facility did not benefit from the traditional therapies with which they had been treated earlier. hESC treatment for all these patients had shown significant improvement; the patients who had complaints of multiple episodes of epilepsy in a day were reduced in majority after hESC therapy. Very few studies have been reported to treat speech disorders using hESC, the CP patients who were treated for speech disorders with our prepared cell lines had shown noticeable improvement; the patients who were unable to speak even a single word before receiving hESC therapy became completely verbal after getting this novel treatment.

Conclusion

hESCs represent a promising source of generating neurons to treat neurological conditions like epilepsy and other motor disturbances like deformed
speech associated with CP. Unlike other conventional treatments discussed, the hESC therapy is able to measure all GMFCS levels for CP and its co-morbidities. The scores show that the hESC treatment has improved the overall well being of the 101 CP patients with a single session of therapy provided. However, future clinical studies are needed to further support our findings.

Acknowledgements
The author acknowledges all the doctors, staff and patients of the NutechMediworld. The author also acknowledges Knowledge Isotopes Pvt. Ltd. (http://www.knowledgeisotopes.com) for the writing support.

Funding
None

Conflicts of interest
No competing interests exist.

Abbreviations
CP: Cerebral Palsy
ADDM: Autism and Developmental Disabilities Monitoring
UCBSCs: Umbilical cord blood stem cells
iPSCs: Induced pluripotent stem cells
hESC: Human embryonic stem cell
IEC: Independent Ethics Committee
IVF: In-vitro fertilization
GMP: Good manufacturing practice
GLP: Good laboratory practice
GTP: Good tissue practice
IM: Intramuscular
IV: Intravenous
GMFCS-E & R: Gross Motor Function Classification System-Expanded and Revised
SPECT: Single-photon emission computed tomography
AEDs: Antiepileptic drugs
SLT: Speech and language therapy
GABA: Gamma amino butyric acid
GDNF: Glial cell-line derived neurotrophic factor
TLE: Temporal lobe epilepsy

References


42. Janice R. Naegle XM. Gene and stem cell therapies for treating epilepsy 2010.


49. Safety and Effectiveness of Banked Cord Blood or Bone Marrow Stem Cells in Children With Cerebral Palsy (CP). (ACT for CP). USA 2015.